Alert detail
LCD L38584: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — CGS
Policy ID: LCD-L38584Specialty: OncologyAdded: 6/5/2026Effective: 2026-04-16lcd
What changed
New MolDX policy may alter tumor cell testing reimbursement.
Who’s affected: Oncology billing teams · Effective: 2026-04-16
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.